A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth

Cancer Prevention Research

Volumn 3, Issue 12, 2010, Pages 1596-1607

  Lambert, James R ^a   Eddy, Vikram J ^b   Young, Christian D ^a   Persons, Kelly S ^b   Sarkar, Sibaji ^b   Kelly, Julie A ^a   Genova, Elizabeth ^a   Lucia, M Scott ^a   Faller, Douglas V ^b   Ray, Rahul ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CALCITRIOL; CALCITRIOL 3 BROMOACETIC ACID; CALCITRIOL DERIVATIVE; CASPASE 3; CASPASE 7; CASPASE 9; CYCLIN A; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ALKYLATING AGENTS; ALKYLATION; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCITRIOL; CASPASES; CELL CYCLE; CELL PROLIFERATION; CYCLIN A; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CALCITRIOL; TUMOR CELLS, CULTURED; VITAMIN D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650339262     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0122     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. van Spronsen DJ, Mulders PF, de Mulder PH. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2005;55:177-91.
3. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005;66:1-9. (Pubitemid 41356552)
4. Mancuso A, Sternberg CN. New treatments for metastatic kidney cancer. Can J Urol 2005;12(Suppl 1):66-70.
5. Ko YJ, Atkins MB. Chemotherapies and immunotherapies for metastatic kidney cancer. Curr Urol Rep 2005;6:35-42.
6. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.
7. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005;16:83-95. (Pubitemid 40691207)
8. Matsuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 2006;5:797-808. (Pubitemid 43724578)
9. Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;65: 33-40.
10. Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:1216-23.
11. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006;106:2136-42.
12. Ray R, Swamy N, MacDonald PN, Ray S, Haussler MR, Holick MF. Affinity labeling of the 1 alpha,25-dihydroxyvitamin D3 receptor. J Biol Chem 1996;271:2012-7.
13. Swamy N, Xu W, Paz N, Hsieh JC, Haussler MR, Maalouf GJ, et al. Molecular modeling, affinity labeling, and site-directed mutagenesis define the key points of interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1α,25-dihydroxyvitamin D3. Biochemistry 2000;39:12162-71.
14. Chen ML, Ray S, Swamy N, Holick MF, Ray R. Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1α,25-dihydroxyvitamin D3-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1α,25-dihydroxyvitamin D3. Arch Biochem Biophys 1999;370:34-44. (Pubitemid 29476947)
15. Swamy N, Persons KS, Chen TC, Ray R. 1α,25-Dihydroxyvitamin D3- 3beta-(2)-bromoacetate, an affinity labeling derivative of 1α,25- dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. J Cell Biochem 2003; 89:909-16.
16. Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, et al. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3β-(2)-bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res 2004;10:8018-27.
17. Lambert JR, Young CD, Persons KS, Ray R. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells. Biochem Biophys Res Commun 2007;361:189-95. (Pubitemid 47102284)
18. Lange TS, Singh RK, Kim KK, Zou Y, Kalkunte SS, Sholler GL, et al. Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma. Chem Biol Drug Des 2007;70:302-10. (Pubitemid 47537692)
19. Ray R, Ray S, Holick MF. 1α,25-Dihydroxyvitamin D3-3-bromoacetate, an affinity labeling analog of 1α,25-dihydroxyvitamin D3 receptor. Bioorg Chem 1994;22:276-83.
20. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197-207.
21. Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm, J Biol Chem 2003;278:46862-8.
22. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 2001;61:7122-9.
23. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at twopoints in thehuman cell cycle.EMBOJ 1992;11: 961-71.
24. Aaltomaa S, Lipponen P, la-Opas M, Eskelinen M, Syrjanen K, Kosma VM. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 1999;80:2001-7. (Pubitemid 29391288)
25. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:10-7.
26. Simoli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58:367-76. (Pubitemid 26348970)
27. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51. (Pubitemid 26413787)
28. Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H. Inhibitory effect of 1-alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Intl 1986;29:834-40. (Pubitemid 16094010)
29. Fuzioka T, Hasegawa M, Ishikura K, Matsuhita Y, Sato M, Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 1988;160:247-51.
30. Trydal T, Bakke A, Aksnes L, Aarskog D. 1,25-Dihydroxyvitamin D3 receptor measurement in primary renal cell carcinomas and autologous normal kidney tissue. Cancer Res 1988;48:2458-61.
31. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803. (Pubitemid 41215743)
32. Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase. Akt, Expert Opin Investig Drugs 2004;13:787-97.
33. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005;16:928-33. (Pubitemid 40903919)
34. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-67.
35. Purdue MP, Johansson M, Zelenika D, et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet. In press 2010.
36. Chow W-H, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-57.